Increasing ovarian cancer cases are fueling expansion in the hereditary breast and ovarian cancer treatment market
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Progress Between 2026 And 2030?
Significant expansion has been observed in the hereditary breast and ovarian cancer syndrome treatment market size over recent years. It is anticipated to grow from $7.07 billion in 2025 to $7.47 billion in 2026, at a compound annual growth rate (CAGR) of 5.6%. The market’s historical growth is attributable to increasing awareness of hereditary cancer syndromes, the availability of brca mutation testing, the expansion of cancer screening infrastructure, the rising use of hormonal therapies, and the growth of specialized oncology clinics.
The hereditary breast and ovarian cancer syndrome treatment market is projected to experience substantial expansion in the coming years. This market is forecast to reach $9.69 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.7%. Key drivers for this anticipated growth include the broadening of personalized oncology treatments, a rise in preventive surgical procedures, advancements in targeted and immunotherapy development, increased funding for genetic diagnostics, and enhanced solutions for long-term patient monitoring. Significant trends expected during this period involve a greater uptake of genetic counselling services, an increase in preventive therapeutic strategies, the expanding incorporation of targeted cancer therapies, the broadening of risk-based screening initiatives, and a heightened emphasis on early intervention methods.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Strong Drivers Are Impacting The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Growth?
The increasing occurrence of ovarian cancer is anticipated to boost the expansion of the hereditary breast and ovarian cancer syndrome treatment market in the future. This condition is characterized by a malignant tumor forming in the ovaries, which are female reproductive organs vital for producing eggs and hormones. Factors contributing to this trend include greater longevity, postponing childbearing, and evolving lifestyle habits. Hereditary Breast and Ovarian Cancer Syndrome (HBOC) refers to a genetic disorder that elevates the risk of developing breast, ovarian, and various other cancers. As an example, the World Ovarian Cancer Coalition, a Canada-based non-profit organization, reported in April 2024 that around 324,603 women globally were diagnosed with ovarian cancer in 2022. Projections indicate that by 2050, the yearly incidence of cases will near half a million, representing a 55% rise. Consequently, the growing prevalence of ovarian cancer is a key factor stimulating the expansion of the hereditary breast and ovarian cancer syndrome treatment market.
How Is Segmentation Applied In The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Segment Analysis?
The hereditary breast and ovarian cancer syndrome treatment market covered in this report is segmented –
1) By Treatment: Hormonal Therapy, Chemoprevention, Genetic Counselling, Medication, Other Treatments
2) By Diagnosis: Genetic Testing, Magnetic Resonance Imaging (MRI), Mammography, Other Diagnosis
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors
2) By Chemoprevention: Tamoxifen, Raloxifene
3) By Genetic Counselling: Risk Assessment, Family Planning Guidance
4) By Medication: Targeted Therapies, Immune Checkpoint Inhibitors
5) By Other Treatments: Preventive Surgery, Surveillance Strategies
Which Trends Are Contributing To Changes In The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
Leading enterprises in the hereditary breast and ovarian cancer syndrome treatment market are embracing innovative therapeutic approaches, like comprehensive risk evaluations, to deliver dependable services to their clientele. Such complete risk assessment tests serve as instruments to determine an individual’s propensity for developing a disorder or manifesting symptoms of an illness. An example of this is seen in February 2023 when Genetic Technologies Limited, an Australia-based molecular diagnostics firm, introduced an innovative comprehensive risk assessment test, which functions as a treatment modality for breast and ovarian cancer. This particular test integrates gene mutation screening for both breast and ovarian cancers, taking into account hereditary and non-hereditary risk factors, alongside the GeneType risk score applicable to both conditions. Its distinct methodology unifies the identification of the 13 key actionable genes associated with breast and ovarian cancer susceptibility with the established GeneType test platform. The new testing platform is specifically designed for women over 30 years of age who, even without unusual genetic anomalies, face an elevated risk of developing breast and ovarian cancer within the broader population.
Who Are The Companies Participating In The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Environment?
Major companies operating in the hereditary breast and ovarian cancer syndrome treatment market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co., AbbVie Inc., Bayer AG, Sanofi-Aventis LLC, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Seagen Inc., Genentech Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Myriad Genetics Inc., Invitae Corporation, Natera Inc., LifeLabs Genetics, Abbott Laboratories
Get The Full Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Report:
Which Region Leads The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market In Terms Of Market Share?
North America was the largest region in the hereditary breast and ovarian cancer syndrome treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary breast and ovarian cancer syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market 2026, By The Business Research Company
Breast Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report
Hereditary Cancer Testing Market Report 2026
https://www.thebusinessresearchcompany.com/report/hereditary-cancer-testing-global-market-report
Ovarian Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/ovarian-cancer-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
